GlobeNewswire·Sep 9, 2026, 9:00 AM ET

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys Inc. (NASDAQ: FEMY) announced a partnership with CapexMD to expand patient access to its FemaSeed-led fertility portfolio through dedicated financing solutions.
The collaboration supports access to FemaSeed Complete, an in-office intratubal insemination solution, alongside FemVue ® and SpermVue ® fertility diagnostics across OB/GYN practices and fertility centers.
CEO Kathy Lee-Sepsick stated the financing option aims to reduce financial barriers for patients seeking first-line fertility treatment at lower costs than IVF.
CapexMD Client Relations Director A.J. Rosenfield highlighted the partnership as an expansion of their 17-year focus on simplifying fertility financing for practices, pharmacies, and patients.
The Femasys Fertility Portfolio combines diagnostic evaluation tools with FemaSeed Complete and FemSperm to enable earlier, less invasive, and more accessible fertility care without specialist referrals.
Femasys is advancing FemBloc ®, a non-surgical permanent birth control solution, toward U.S. FDA approval via the FINALE trial, following 2025 regulatory approvals in Europe, the UK, and New Zealand.
CapexMD provides financing for multiple aspects of fertility care, including treatments, medications, testing, and donor services, while consolidating costs into single solutions.
The press release includes standard forward-looking statements regarding regulatory approvals, clinical trial outcomes, and commercialization risks for Femasys products.